Cited by 146Ethics in Clinical ResearchEthics and bioethics in healthcareBiomedical Ethics and Regulation

The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index; 42 of the 117 sources its claims cite were checked for support.

Lessons from HeLa Cells: The Ethics and Policy of Biospecimens

Open access
Beskow, Laura M.·2016·Annual Review of Genomics and Human Genetics

Abstract

Human biospecimens have played a crucial role in scientific and medical advances. Although the ethical and policy issues associated with biospecimen research have long been the subject of scholarly debate, the story of Henrietta Lacks, her family, and the creation of HeLa cells captured the attention of a much broader audience. The story has been a catalyst for policy change, including major regulatory changes proposed in the United States surrounding informed consent. These proposals are premised in part on public opinion data, necessitating a closer look at what such data tell us. The development of biospecimen policy should be informed by many considerations—one of which is public input, robustly gathered, on acceptable approaches that optimize shared interests, including access for all to the benefits of research. There is a need for consent approaches that are guided by realistic aspirations and a balanced view of autonomy within an expanded ethical framework.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This review uses the Henrietta Lacks/HeLa case to examine ethics and policy for biospecimen research, especially informed consent and proposed US regulatory changes. It argues that public opinion data are more complex than the NPRM suggests and that consent should be part of a broader ethical framework with oversight and balanced autonomy.

Key findings

  • The HeLa controversy helped catalyze proposed US regulatory changes: the 2015 NPRM would define a human subject to include living individuals about whom an investigator “obtains, uses, studies or analyzes biospecimens” regardless of identifiability, and would generally require consent for research use of all biospecimens, including broad consent for future unspecified research and exemptions for secondary use with safeguards.
  • The public opinion studies cited by the NPRM do not show consensus: Kaufman et al. (n = 4,659) found 48% preferred broad consent, 42% study-specific consent, and 10% categorical consent; a subset (n = 3,347) found 51% broad vs. 49% study-specific. Vermeulen et al. (n = 133) found 43% preferred opt-out plus, 34% one-time consent, 16% standard opt-out, and 8% no information. Simon et al. (n = 48 focus groups; n = 751 survey) found 63%/67% preferred opt-in initial consent, with broad consent preferred by 54%/41%, study-specific by 21%/29%, and categorical by 21%/25%.
  • Preference differs from acceptability: in Simon et al., opt-out was preferred by only 18% but supported by 78%; in Ewing et al., 76% of broad-consent and 74% of study-specific-consent respondents said they would participate. The paper also argues informed consent cannot bear the weight asked of it: consent forms are too long and complex, comprehension is often poor, and across four systematic reviews only one-on-one discussion consistently improved understanding.
  • The author recommends broad consent coupled with oversight, active opt-out for residual clinical specimens, and expanded ethical frameworks that balance autonomy with other principles and ensure research benefits are accessible to all.

Methods

  • Narrative review and critical synthesis, not a systematic review or new empirical study.
  • Draws on the HeLa case, current US Common Rule and the 2015 NPRM, public opinion studies cited by the NPRM, systematic reviews of biobanking attitudes, and informed consent literature.
  • Main analysis compares proposed biospecimen policy against empirical public opinion data and ethical principles, then discusses consent models and alternatives.

Limitations

  • Stated: public opinion data are not definitive; attitudes may reflect misunderstanding, bias, selfishness, self-deception, or other problematic factors, and public opinion alone should not dictate policy.
  • Stated: reviews of biobanking attitudes are limited by heterogeneous underlying studies, and hypothetical scenarios may not accurately predict real-life behavior; evidence on consent interventions is notably limited.
  • Evident from the text: this is a single-author narrative review with no systematic search strategy or new data collection, and its policy focus is primarily on the United States.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1146/annurev-genom-083115-022536

Cites

147 of 147 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

20 No full text of the sources · 16 Supported · 14 Own interpretation · 13 Partly supported · 11 Not checked yet · 6 Supported so far · 3 Sources not found · 2 Not supported · 2 No basis given · accuracy not yet measured

Verify all 11 references — free account
  • It may state two separate claims as one. 46
  • Probably not a substantial claim. 28
57 of 57
  • The paper relies on this without support.

    Many if not most people have no preexisting knowledge or opinions about biobanking or the ethical and policy issues and controversies so familiar to “experts.”

    “Many if not most people have no preexisting knowledge or opinions about biobanking or the ethical and policy issues and controversies so familiar to “experts.””
  • The paper relies on this without support.

    The Common Rule was developed in response to revelations of extreme research abuses of vulnerable populations and was designed primarily to protect human beings from physical risks involved in experimental research.

    “In the United States, federal regulations (known as the Common Rule) were developed in response to revelations of extreme research abuses of vulnerable populations; these regulations were designed primarily to protect human beings from physical risks involved in experimental research.”
  • The paper relies on this without support.

    Complete deidentification of biospecimens and data is illusory.

    “These have occurred in the context of rapid scientific and technological innovation and the inescapable recognition that complete deidentification of biospecimens and data is illusory.”
  • The paper relies on this without support.

    Proposed regulatory changes look prominently to routine consent for research use of biospecimens, regardless of whether they were originally collected for research or clinical purposes.

    “As a solution, proposed regulatory changes look prominently to routine consent for research use of biospecimens, regardless of whether they were originally collected for research or clinical purposes.”
4 of 4

Citations

Cites

Show all 147 references

Research works printed but not linked: 11

  1. Albala I, 2010, IRB, 32, 7
  2. Feldman R, 2011, Stanford Law Rev., 63, 1377
  3. Jones HW, 1971, Obstet. Gynecol., 38, 945
  4. Paasche-Orlow MK, 2013, IRB, 35, 12
  5. Ram N, 2008, Jurimetrics, 48, 253
  6. Royston I, 1985, Clin. Res., 33, 442
  7. Schulman AN, 2012, New Atlantis, 35, 99
  8. Skloot R, 2001, New York Times
  9. Skloot R, 2013, New York Times
  10. Stone J, 1988, Discover, 9, 33
  11. US Dep. Health Hum. Serv, 2008, Guidance on research using coded private information or specimens

Cited by

Sorted by citations

See all 146

Metadata

Authors
Beskow, L. M.
Affiliations
Duke University (US)
Corresponding author
Beskow, Laura M.
Venue
Annual Review of Genomics and Human Genetics
Published
2016-08-31
Volume
17
Issue
1
Pages
395-417
ISSN
  • 1527-8204 (ISSN-L)
  • 1545-293X
OpenAlex
W2297837302
Cited by
146
References
147
Citations by year
2026: 15 · 2025: 22 · 2024: 12 · 2023: 23 · 2022: 21 · 2021: 20 · 2020: 13 · 2019: 8 · 2018: 5 · 2017: 5 · 2016: 2
FWCI
0.99
Type
journal article
Language
en
Open access
Locations
  • Annual Review of Genomics and Human Genetics (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion, cc-by)
  • PubMed Central (acceptedVersion, cc-by)
Funders
  • National Institutes of Health (UL1TR001117, 7r01hg007733-04)
  • National Human Genome Research Institute (R01HG006621, R01-HG-007733)
  • U.S. National Library of Medicine (R01LM012178)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics and bioethics in healthcare
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
Keywords
HeLa cells, Henrietta Lacks, human biospecimens, informed consent, public opinion, research autonomy
MeSH terms
HeLa Cells, Humans, United States, Biological Specimen Banks

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review